MedTrace Logo

California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA

NCT03469947 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-07-30

No results posted yet for this study

Summary

The California Prehospital Antifibrinolytic Therapy (Cal-PAT) study seeks to evaluate the safety and efficacy of Tranexamic Acid (TXA) use in the civilian prehospital and in hospital setting in cases of traumatic hemorrhagic shock.

Conditions

  • Hemorrhagic Shock
  • Trauma Injury

Interventions

DRUG

Tranexamic Acid

1 gram of prehospital Tranexamic Acid

Sponsors & Collaborators

  • Arrowhead Regional Medical Center

    lead OTHER

Principal Investigators

  • Michael Neeki · Arrowhead Regional Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2024-07-29
Completion
2024-07-29
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03469947 on ClinicalTrials.gov